Insider-Owned Growth Companies Leading The Global Market In June 2025

As global markets navigate the complexities of trade policies and fluctuating inflation rates, U.S. stocks have shown resilience with notable gains in major indices, despite some late-week selling pressures. In this environment, growth companies with high insider ownership stand out as potentially robust investments due to their alignment of interests between management and shareholders, which can be especially advantageous amidst ongoing economic uncertainties.

Top 10 Growth Companies With High Insider Ownership Globally

Click here to see the full list of 840 stocks from our Fast Growing Global Companies With High Insider Ownership screener.

Below we spotlight a couple of our favorites from our exclusive screener.

3Peak (SHSE:688536)

Simply Wall St Growth Rating: ★★★★★☆

Overview: 3Peak Incorporated focuses on the research, development, and sale of analog integrated circuit products both in China and internationally, with a market cap of CN¥19.06 billion.

Operations: The company generates revenue of CN¥1.44 billion from its operations in the integrated circuit industry.

Insider Ownership: 14.2%

Revenue Growth Forecast: 26.6% p.a.

3Peak's revenue is projected to grow significantly at 26.6% annually, outpacing the Chinese market's average growth rate. The company recently reported a turnaround with a net income of CNY 15.56 million for Q1 2025, compared to a loss the previous year. Despite high volatility in its share price and low forecasted return on equity, it's expected to achieve profitability within three years, reflecting strong growth potential amid stable insider ownership dynamics.

• Get an in-depth perspective on 3Peak's performance by reading our analyst estimates report here.
• Our valuation report unveils the possibility 3Peak's shares may be trading at a premium.

Qi An Xin Technology Group (SHSE:688561)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Qi An Xin Technology Group Inc. is a cybersecurity company offering products and services to government, enterprises, and other institutions in China and internationally, with a market cap of CN¥20.58 billion.

Operations: The company generates revenue from the Information Security Industry segment, amounting to CN¥4.33 billion.

Insider Ownership: 22%

Revenue Growth Forecast: 19.3% p.a.

Qi An Xin Technology Group is poised for growth with revenue expected to increase at 19.3% annually, surpassing the Chinese market's average. Despite a net loss of CNY 417.68 million in Q1 2025, the company is forecasted to become profitable within three years, indicating robust growth potential. It trades at a significant discount to its estimated fair value and recently announced a CNY 300 million private placement, pending shareholder approval, suggesting strategic financial maneuvers amidst stable insider ownership.

• Click here to discover the nuances of Qi An Xin Technology Group with our detailed analytical future growth report.
• In light of our recent valuation report, it seems possible that Qi An Xin Technology Group is trading behind its estimated value.

Zhejiang Jolly PharmaceuticalLTD (SZSE:300181)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Zhejiang Jolly Pharmaceutical Co., LTD is involved in the research, production, and marketing of Chinese medicinal products both domestically and internationally, with a market cap of CN¥11.11 billion.

Operations: Zhejiang Jolly Pharmaceutical Co., LTD generates its revenue primarily through the research, production, and marketing of Chinese medicinal products in both domestic and international markets.

Insider Ownership: 23.1%

Revenue Growth Forecast: 20.4% p.a.

Zhejiang Jolly Pharmaceutical shows promising growth with revenue expected to rise 20.4% annually, outpacing the Chinese market. Despite a dividend yield of 3.38% not fully covered by free cash flows, the company trades at a good value compared to peers and is priced significantly below its estimated fair value. Recent earnings reports indicate strong financial performance with increased sales and net income year-over-year, while insider ownership remains stable without substantial recent trading activity.

• Click to explore a detailed breakdown of our findings in Zhejiang Jolly PharmaceuticalLTD's earnings growth report.
• The analysis detailed in our Zhejiang Jolly PharmaceuticalLTD valuation report hints at an deflated share price compared to its estimated value.

Where To Now?

• Click here to access our complete index of 840 Fast Growing Global Companies With High Insider Ownership.
• Seeking Other Investments? Uncover 19 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com